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four with a signiﬁcant increase in ARP, and two with a signiﬁcant
increase in OPC (p < 0.05). By comparison, Medicare Part D
resulted in signiﬁcant TRx increases for ten drugs (and no
decreases), eight showed ARP increases and two had ARP
decreases (p < 0.05). Interestingly, seen drugs decreased OPC
while two increased (p < 0.05). CONCLUSIONS: NICE HTAs
had mild effects on the prescription utilization and costs in the
US, while Medicare Part D caused fundamental changes to the
market parameters measured. The inﬂuence of NICE decisions
on the US market should be monitored as HTAs are expected to
play a more signiﬁcant role in the advent of Medicare Part D
Reimbursement.
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OBJECTIVES: Health technology assessment is used to inform
reimbursement decisions for pharmaceuticals in many countries.
The political and administrative contexts in which HTA is used
vary considerably between countries, as do the decisions on
individual products. The aim of this study was to investigate the
inﬂuence of HTA and other factors on reimbursement decisions.
METHODS: A systematic search was conducted to obtain the
documentation for reimbursement decisions on cancer and car-
diovascular medicines. Where insufﬁcient information was pub-
lished, or reports were not available in English, decisions were
excluded. The analysis was conducted using discrete response
models and included methods of assessment, evidence included
and stakeholder involvement. RESULTS: Detailed information
was obtained on 194 decisions from Australia, Belgium, Canada,
England, France, Scotland and Sweden. The pooled analysis
showed that 27% of medicines were recommended, 41% were
recommended for restricted use and 32%were not recommended.
The multinomial logistic regression showed that the number of
RCTs, disease area, use of sensitivity analysis and public interest
had a statistically signiﬁcant impact upon decisions. The use of
cost-utility analysis in the supporting HTA was found to reduce
the probability of a positive recommendation. The analysis for
those countries that included cost-utility analysis showed that the
value of the ICER had a statistically insigniﬁcant impact upon the
decision.However, a sub-analysis for decisions in England showed
that this was found to be statistically signiﬁcant. CONCLU-
SIONS:These ﬁndingsmay reﬂect varying approaches to conduct-
ing economic analysis, differences in cost-effectiveness thresholds
and variation in the weight given to economic evidence in inform-
ing decisions within countries. The individual product level
factors explain some of the variation in reimbursement decisions
across countries. Further variationmay be explained by the health
system and policy context in which decisions are made. The next
stage of the work will investigate these factors directly.
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OBJECTIVES: Early-stage medical technology assessment
(MTA) is sometimes conducted in an ad-hoc manner, if it is
performed at all. Identiﬁcation of universal steps in early-stage
MTA would catalyze the development of valuable technology.
METHODS: Universal steps in early-stage MTA were developed
following evaluation of a new stroke rehabilitation strategy tar-
geting the urban Chinese population. Literature review, physician
and patient interviews, and decision modelling were performed
to appraise current stroke care and evaluate methods to improve
it. Different rehabilitation strategies were recognised and
described, and their costs and health effects were estimated and
compared. RESULTS: Certain universal steps in early-stage MTA
could be identiﬁed. An important ﬁrst step is the creation of a
detailed study plan that includes evaluation criteria and may also
discuss the value of a disease progression model. A second step
consists of qualitative and quantitative descriptions of current
treatments and new technologies. This step focuses not simply
on acquiring quantitative estimates of costs, health effects and
quality of care, but also on identifying areas for quality improve-
ment. Since the literature review did not yield sufﬁcient informa-
tion, other methods (i.e., interviews) were needed to ascertain
attitudes regarding usual care and behaviour. These methods
provided extra insight into physician and patient preferences,
insight that was used to modify the evaluation criteria. Subse-
quently, the new technology was described both qualitatively and
quantitatively. Lastly, the costs and health effects of the treat-
ments were compared using standard techniques (e.g., uncer-
tainty analysis). These results identiﬁed where more information
needed to be collected. CONCLUSIONS: As with later-stage
MTA, there is a need and an opportunity to develop universal
steps for conducting early-stage MTA. They supplement, but do
not replace, the steps and techniques applied during later-stage
assessments. If properly formulated, they can be used to facilitate
good internal decision-making during the development phase.
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OBJECTIVES: In England only new innovative technologies
evaluated useful and cost effective are taken up by health care
providers. NICE leads the way for this managed entry, but delays
in publication of guidance, and the fact it only covers tech-
nologies with the potential to have large ﬁnancial impact, leaves
local payers looking to other technology appraisal groups for
guidance—often local groups, to review a technology in line with
local needs, demographics and priorities. There are more than 30
of these review groups operating in England, on either a national
or local level which inﬂuence prescribing, funding, and commis-
sioning decisions. This research was undertaken to understand,
and map the inﬂuence of these organizations. METHODS: A
total of 65 senior mangers from SHAs, PCTs, hospital Trusts, and
HTA organsiations were interviewed, using qualitative and quan-
titative measures, to provide an indication of the current, and
future inﬂuence of HTA organizations in England. RESULTS:
For interventions without forthcoming NICE guidance, NHS
organizations are responsible for accessing publicly available
evidence to determine local policies for managed entry. Notiﬁca-
tion of new drugs is generally from one of the national informa-
tion portals. In the absence of NICE guidance, the SMC is, for
most, the next port of call. If there is no NICE, or SMC guidance,
HCPs generally look to their regional group, or the HTA group
with relevant therapy experience. The remit, focus and inﬂuence
of the different regional groups was assessed and found to vary.
CONCLUSIONS: Because of delays in NICE guidance of up to
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two years in many cases, and the fact that NICE does not cover
middle ground therapies, other HTA organizations have a sig-
niﬁcant impact on funding, prescribing, and commissioning deci-
sions in England. Their inﬂuence varies regionally, depends on
their remit and focus, and need to be understood, and accounted
for to ensure the appropriate uptake of technologies by health
care providers in England, now, and in the foreseeable future.
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OBJECTIVES: To evaluate the information about current
activities of worldwide agencies for Health Technology Assess-
ment (HTA) and assess whether the information disseminated
by the agencies is sufﬁcient to ensure timely and effective infor-
mation sharing with stakeholders. METHODS: Targeted
searching of the websites of all members of the International
Network of Agencies for Health Technology Assessment
(INAHTA) was conducted to retrieve relevant information. Sec-
ondary research was supplemented with a survey administered
directly to target organizations in each country. RESULTS: The
results of these searches totalled 815 references to on-going
assessments. They fall into some broad categories, which
include HTA, systematic reviews, primary research, clinical
guidelines, observational studies and registries. About 5% of
the references identiﬁed were assessing medical devices, 18%
assessing drugs (pharmaceuticals, biologicals, vaccines), and
76% other technologies (medical or surgical procedure, orga-
nization or administrative system, support system or others).
Agency’s key communication form is Internet; in one out of ﬁve
cases not available in English. About 50% of the agencies (24
out of 46) have a section about current assessments on their
website. Out of the 22 agencies without information on the
internet, 68% were readily responsive to requests for informa-
tion; 36% providing full project details (e.g., application name,
assessment process, stage and timeline). CONCLUSIONS:
Health care agencies routinely use centralized assessments for
(new) medicines and other health technologies. While ISPOR
Special Interest groups have gathered insights on the current
methods and applications of technology assessments across
worldwide HTA agencies, the access to on-going assessments is
limited. The examples above show the lack of transparency and
inconsistency in the information disseminated by the agencies.
This complicates early access to information needed to get
insights in recent developments and trends in health policy.
This not only negatively impedes on the industry but one might
question the impact on patient care.
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OBJECTIVES: In mid 2007 the U.S. Centers for Medicare and
Medicaid Services (CMS) implemented a Medicare quality incen-
tive program for physicians and other professionals paid under
the Medicare Physician Fee Schedule (PFS). This study examines
the development and expansion of that program in to 2008 and
beyond and illustrates its growing emphasis on disease manage-
ment. METHODS: PQRI regulatory guidance was reviewed and
analyzed for changes from the 2007 program. Criteria for suc-
cessful compliance were arrayed according to the method of
participation: claims-based, measures groups and registry report-
ing. A list of current PQRI resources was compiled. RESULTS:
The Medicare, Medicaid, and SCHIP Extension Act of 2007
(MMSEA), enacted on December 29, 2007 (Pub. Law 110–173),
authorized the continuation of the Physician Quality Reporting
Initiative (PQRI) for 2008 and 2009, and authorized CMS to
establish greater ﬂexibility within the program. In addition to the
original claims-based reporting, new options include: 1) alterna-
tive reporting criteria and periods for the reporting of measures
groups, and 2) submission of quality data through clinical data
registries. For 2008, eligible professionals who meet the criteria
for satisfactory submission of quality measures data will earn an
incentive payment of 1.5 percent of their total allowed charges
for PFS covered professional services furnished during the 2008
calendar year. Financial incentives earned for 2008 reporting will
be paid in mid-2009 from the Federal Supplementary Medical
Insurance (Part B) Trust Fund. For 2008 PQRI consists of 119
quality measures, a 61% increase over 2007. CONCLUSIONS:
During 2008 PQRI requirements have diversiﬁed and expanded,
allowing providers more choices in how they participate. The
expanded options for data submission tend toward a more com-
prehensive, disease management perspective than did the initial
2007 process, and also include a measures group for preventive
care.
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OBJECTIVES: A review of the cost and usage for all medicines
and antibiotics in Serbia in 2004–2007, as well as the data on
medicines usage for these two groups. The importance of collect-
ing data on antibiotics consumption is in correlation with ratio-
nal use. METHODS: Medicine and Medical Devices Agency of
Serbia is authorised for collecting and processing data on medi-
cines consumption. Data on medicine consumption in 2004–
2007 was gathered from obliged entities, processed by the DDD/
1000 inh/d and ATC classiﬁcation, and the analyses of ﬁnancial
indicators is done as well. RESULTS: It was established that the
total medicines marketing in Serbia in 2004 was €340 million
(20% for antiinfectives for systematic use—J group), in 2005 it
was € 380 million (19% for J group), in 2006 it was €510 million
(18% for J group) and in 2007 it was € 690 million (17% for J
group). By processing consumption data as DDD, from 2004–
2007 consumption of J group was 34.74, 36.38, 34.21 and 46.51
DDD/1000 inh/d, respectively. Expenditure of subgroup penicil-
lins with extended spectrum was at the ﬁrst place (12 DDD/
1000 inh/d in 2004 and 2005, 11 DDD/1000 inh/d in 2006 and
15 DDD/1000 inh/din in 2007), then tetracyclines (6 DDD/
1000 inh/d in 2004, 5 DDD/1000 inh/d in 2005–2007) and
ﬁrst-generation cephalosporins (around 5 DDD/1000 inh/d in
2004–2007). The consumption of amoxicillin was the highest in
all four years, around 9 DDD/1000 inh/d, at the second place
was doxycycline (6 DDD/1000 inh/d in 2004 and around 5
DDD/1000 inh/d in 2005–2007). CONCLUSIONS: Data useful
for the improvement of pharmacotherapy and its realisation are
generated through processing and analysing the structure of
medicines, and getting the insight of all other factors necessary
for the health care.
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